Keraring implantation effective against keratoconus

Article

In a recent study it has been reported that an intrastromal corneal ring segment implantation is a safe and effective treatment for keratoconus.

In a recent study it has been reported that an intrastromal corneal ring segment implantation is a safe and effective treatment for keratoconus. The study has been published in Cornea.

Led by Dr Anl Kubaloglu, Dr Lütfi Kırdar Kartal Training and Research Hospital, 2nd Eye Clinic, Istanbul, Turkey, the researchers evaluated the safety and efficacy of the Keraring (Mediphacos) implant using both mechanical and femtosecond-assisted tunnel creation to treat patients suffering from keratoconus.

The study comprised 96 eyes from 75 patients, all of whom had contact lens intolerance and clear corneas. A femtosecond laser was used to create corneal tunnels in 26 of the eyes (femtosecond group) and in the remaining 70 eyes it was created mechanically (mechanical group). The Keraring was implanted into each eye and once completed a full ophthalmic examination was performed.

It was demonstrated that the mean best spectacle corrected visual acuity improved during the follow up period and it was also noted that there was a significant decrease in the spherical equivalent refractive error. Additionally, the mean maximum keratometry (Kmax) decreased during the 18 month follow up period. The researchers found that there was no statistically significant difference between the femtosecond and mechanical groups for any parameter.

Based on the results it was concluded that the Keraring implantation is effective for the treatment of keratoconus, providing safety and good visual outcomes after both mechanical and femtosecond assisted tunnel creation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.